R-CHOP Protocol

DRUG5 trials

Sponsors

University of Chicago, Huiqiang Huang, Sun Yat-sen University

Conditions

ALK-Positive Anaplastic Large Cell LymphomaB Cell LymphomaDiffuse Large B Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)EBV-Positive DLBCL, NosEBV-Positive Diffuse Large B-Cell Lymphoma, NosFollicular Lymphoma Grade IIIbHigh-grade B-cell Lymphoma

Phase 1

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Huiqiang HuangALK-Positive Anaplastic Large Cell Lymphoma, Diffuse Large B Cell Lymphoma, EBV-Positive DLBCL, Nos +3

Start: 2020-04-24End: 2025-12-30Target: 140Updated: 2022-04-14

Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

RecruitingNCT05577364

Sun Yat-sen UniversityEBV-Positive Diffuse Large B-Cell Lymphoma, Nos

Start: 2022-11-01End: 2026-02-28Target: 54Updated: 2023-12-14

Phase 2

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Active, not recruitingNCT03995147

University of ChicagoB Cell Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma +2

Start: 2019-08-29End: 2027-02-20Updated: 2025-06-08

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

RecruitingNCT06517511

Sun Yat-sen UniversityDiffuse Large B Cell Lymphoma

Start: 2024-08-01End: 2028-04-01Target: 42Updated: 2026-02-12

Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）

RecruitingNCT06647940

Sun Yat-sen UniversityDiffuse Large B Cell Lymphoma (DLBCL)

Start: 2024-11-01End: 2027-03-01Target: 39Updated: 2024-10-22

Related Papers

Preliminary results of first-line selinexor plus R-CHOP in TP53-mutated diffuse large B-cell lymphoma (Smart trial): A single-arm, phase II trial

Blood2025-11-03

Preliminary result of first-line orelabrutinib plus R-CHOP in CD5-positive diffuse large B-cell lymphoma (Rocket trial): A single-arm, phase II trial

Blood2025-11-03

Combination anti-PD1 antibody and rituximab followed by R-CHOP for newly diagnosed DLBCL in elderly patients: Updated results of the phase II TREND trial

Blood2025-11-03

P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL

HemaSphere2023-08-01

Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial

Blood2022-11-15